13F Holdings
中文EN

ABCL AbCellera Biologics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1703057 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY92.1%
TTM net income YoY13.6%
TTM EPS YoY15.8%
Revenue 3-yr CAGR10.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-298.0%
Net margin-218.5%
FCF margin-48.4%
EBITDA margin-264.0%

Returns

ROE-14.6%
ROA-10.4%
ROIC (approx.)-18.2%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets29.2%
Debt / equity0.00x
Current ratio12.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue25.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.64M$4.05M$8.31M$44.85M$8.96M$17.08M$4.24M$5.05M
R&D expense$43.53M$45.99M$46.66M$50.09M$55.03M$39.21M$42.50M$46.08M
SG&A expense$13.61M$13.85M$12.33M$25.98M$24.96M$21.99M$19.07M$16.02M
Operating income-$53.31M-$62.78M-$57.52M-$28.58M-$76.28M-$49.59M-$62.66M-$72.75M
Pretax income-$42.81M-$58.97M-$49.54M-$19.50M-$68.77M-$36.34M-$52.98M-$46.83M
Income tax-$2.05M-$3.54M-$6.37M-$10.55M-$11.65M-$1.62M-$7.36M-$12.62M
Net income-$40.76M-$55.43M-$43.16M-$8.95M-$57.12M-$34.73M-$45.62M-$34.21M
EBITDA-$46.51M-$55.79M-$50.68M-$26.19M-$71.03M-$44.12M-$57.33M-$70.66M
EPS (basic)-0.13-0.18-0.14—-0.19-0.12-0.15—
EPS (diluted)-0.13-0.18-0.14—-0.19-0.12-0.15—
Weighted avg. shares (diluted)318.05M305.56M303.07M—298.88M298.51M297.69M—
Balance sheet
Cash & equivalents$163.80M$120.06M$77.06M$128.51M$108.16M$117.44M$184.27M$156.32M
Receivables$38.29M$38.42M$39.16M$39.41M$71.25M$70.00M$63.61M$31.98M
Inventory$7.57M$7.58M$7.86M$6.34M———$0
Current assets$876.16M$679.23M$664.60M$728.23M$695.14M$742.14M$764.98M$751.37M
Goodwill$47.81M$47.81M$47.81M$47.81M$47.81M$47.81M$47.81M$47.81M
Intangibles$38.39M$36.53M$37.46M$38.38M$39.32M$40.26M$41.19M$42.11M
Total assets$1.50B$1.31B$1.31B$1.36B$1.36B$1.40B$1.34B$1.36B
Current liabilities$70.47M$53.19M$47.29M$64.31M$68.80M$67.02M$75.40M$76.61M
Total liabilities$437.36M$411.56M$369.03M$390.05M$391.95M$394.99M$321.23M$304.47M
Shareholders' equity$1.06B$896.02M$938.08M$966.90M$964.04M$1.01B$1.02B$1.06B
Shares outstanding326.33M306.47M303.95M300.60M299.01M295.76M295.76M295.76M
Cash flow statement
Operating cash flow$26.91M$25.92M-$33.52M-$34.74M-$52.59M-$32.40M-$11.55M-$8.00M
Capital expenditure$1.61M$2.13M$3.83M$9.84M$8.93M$13.37M$10.64M$15.63M
Free cash flow$25.30M$23.79M-$37.35M-$44.59M-$61.52M-$45.77M-$22.19M-$23.63M
Investing cash flow-$183.44M$11.34M-$25.08M$75.14M$36.49M-$31.81M$7.93M$35.70M
Financing cash flow$200.64M$6.39M$7.19M$4.12M$7.37M-$3.38M$5.97M$4.14M
Depreciation & amortization$6.81M$6.99M$6.84M$2.39M$5.25M$5.47M$5.33M$2.10M
Stock-based compensation$11.67M$12.29M$12.01M$12.90M$13.89M$14.21M$14.79M$15.23M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.